Form 4: SpringWorks Therapeutics Executive Sells Shares Under 10b5-1 Trading Plan

Bhavesh Ashar, Chief Commercial Officer of SpringWorks Therapeutics, sold 1,016 shares of common stock at an average price of $61.1891 under a pre-arranged trading plan.

Summary

• On February 20, 2025, Bhavesh Ashar, the Chief Commercial Officer of SpringWorks Therapeutics, sold 1,016 shares of the company's common stock.
• The sale was executed at a weighted average price of $61.1891 per share, with individual transactions ranging from $61.15 to $61.36.
• The transaction was conducted under a pre-arranged trading plan established on March 15, 2024, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.
• Following the sale, Ashar directly owns 62,053 shares of SpringWorks Therapeutics common stock.

Sentiment

Score: 5

Explanation: The document is a routine SEC filing related to an executive's stock sale under a pre-arranged trading plan. It doesn't inherently indicate positive or negative sentiment.

Industry Context

Sales by company executives are a normal part of corporate governance. The fact that this sale was executed under a 10b5-1 trading plan suggests it was pre-planned and intended to avoid any accusations of insider trading.

Stakeholder Impact

• The sale of shares by an executive could be perceived negatively by some shareholders, but the existence of a 10b5-1 trading plan mitigates concerns about insider trading.

Key Dates

Keywords

SpringWorks Therapeutics, SWTX, Bhavesh Ashar, Chief Commercial Officer, stock sale, Form 4, Rule 10b5-1, trading plan, insider trading